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A B S T R A C T
Docosahexaenoic acid (DHA) in infant formula at concentrations based on worldwide human milk has resulted
in circulating red blood cell (RBC) lipids related to visual and cognitive development. In this study, infants
received study formula (17 mg DHA/100 kcal) with a commercially-available (Control: n=140; DHASCO®) or
alternative (DHASCO®-B: n=127) DHA single cell oil from 14 to 120 days of age. No signiﬁcant group
diﬀerences were detected for growth rates by gender through 120 days of age. Blood fatty acids at 120 days of
age were assessed by capillary column gas chromatography in a participant subset (Control: n=34; DHASCO-B:
n=27). The 90% conﬁdence interval (91–104%) for the group mean (geometric) total RBC DHA (µg/mL) ratio
fell within the pre-speciﬁed equivalence limit (80–125%), establishing study formula equivalence with respect
to DHA. This study demonstrated infant formula with DHASCO-B was safe, well-tolerated, and associated with
normal growth. Furthermore, DHASCO and DHASCO-B represented equivalent sources of DHA as measured by
circulating RBC DHA.
1. Introduction
Human milk, the standard for infant feeding and nutrition,
provides the long chain polyunsaturated fatty acid (LCPUFA) docosa-
hexaenoic acid (DHA; 22:6n-3). DHA is present in high concentrations
in brain grey matter and photoreceptor cell membranes of the retina
and accumulates in the central nervous system during the third
trimester in utero and through two years of age [1]. Total red blood
cell (RBC) and plasma phospholipid (PPL) fatty acid composition have
been commonly used as outcomes in studies of infant formulas with
added algal-derived preformed DHA single cell oil (DHASCO®) [2,3]
based on worldwide human milk composition (~0.3% of total fatty
acids) [4,5] and associated with RBC LCPUFAs comparable to those of
breastfed infants [2,3,6], visual and cognitive development in term
infants [2,7–16], and enhanced growth and neural development in
preterm infants [17,18]. DHASCO is derived from the marine micro-
algae Crypthecodinium cohnii; has a history of safe use as the main
DHA source in routine, premature, and other specialty infant formulas
(such as soy and hydrolyzed protein) [2,3,7–11,17–20]; and has been
generally recognized as safe (GRAS) by the US Food and Drug
Administration (FDA) for use in infant formulas since 2001 [21,22].
DHA is currently considered either an optional or mandatory
ingredient for infant formula. As new ingredients appropriate for use
in infant formulas are developed and become commercially available
safety and suitability must be assessed, including sources of DHA.
DHASCO®-B is a new single cell oil derived from another common
marine algae Schizochytrium sp., developed in accordance with Good
Manufacturing Practices, and may be used as a replacement for
DHASCO [23]. Both DHASCO and DHASCO-B are sources of DHA
(minimum of 40% of total fatty acids), the 22 carbon fatty acid with 6
unconjugated double bonds–the ﬁrst of which is located at the third
carbon from the methyl end, with fatty acids predominantly esteriﬁed
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as triacylglycerols, similar to human milk [24]. DHASCO-B is GRAS for
use in preterm and term, exempt and non-exempt infant formulas and
follow-on formulas [25] and is approved as a Novel Food by Health
Canada as a source of DHA for use in infant formula, follow-on infant
formula, and foods for special dietary use for children under 3 years of
age [26]. In addition, oil from the micro-algae Schizochytrium sp. has
been authorized for use in infant and follow-on formula by the
European Commission [27], when used in accordance with the
European regulatory standard on infant formulae and follow-on
formulae [28]. Safety data is available from rodent genotoxicity and
neonatal piglet studies [29,30], the latter considered the most appro-
priate model to safely examine new constituents of infant formula [31].
To evaluate nutritional bioequivalence and safety, DHASCO-B or
DHASCO (each used in a blend with arachidonic acid [ARA] single
cell oil [ARASCO®] in a milk replacer formula) were provided to
preweaning piglets over a 3-week postnatal feeding period; both were
well tolerated with no diﬀerences observed in tissue DHA accretion
(heart, liver and brain) or circulating RBC and plasma DHA [30].
In the present study, we evaluated the eﬀect of an investigational
routine intact protein cow's milk-based ready-to-use (RTU) liquid
formula with DHASCO-B as the source of DHA (17 mg/100 kcal),
ARASCO as the source of ARA (34 mg/100 kcal) and a prebiotic blend
of polydextrose (PDX) and galactooligosaccharides (GOS) (1:1 ratio,
4 g/L) on growth and tolerance in healthy term infants. Rate of weight
gain (g/day) from 14 to 120 days of age was evaluated as the primary
variable to establish that the investigational study formula with
DHASCO-B provided adequate growth compared to the marketed
Control formula with DHASCO. In a subset of study participants, a
secondary objective was to compare group RBC DHA concentrations
(μg/mL) to establish the equivalence with respect to DHA for study
formulas.
2. Methods
2.1. Study population
Healthy 10- to 14-day old infants were recruited at 21 clinical sites
in the United States. Eligible infants were singleton births at 37–42
weeks gestational age with birth weight ≥2500 g and solely formula-fed
at least 24 h prior to randomization. Exclusion criteria included history
of underlying disease or congenital malformation likely to interfere
with normal growth and development or participant evaluation;
feeding diﬃculties or history of formula intolerance; weight at rando-
mization < 98% of birth weight; large for gestational age (as conﬁrmed
from hospital birth records) from mother who was diabetic at child-
birth; and immunodeﬁciency.
2.2. Study design
In this multicenter, double-blind, randomized, controlled, parallel-
group, prospective trial, participants were enrolled between May and
November 2014. Parents or legally authorized representative provided
written informed consent prior to enrollment. The research protocol
and informed consent forms observing the Declaration of Helsinki
(including October 1996 amendment) were approved by the institu-
tional review board/ethics committee of each participating institution.
The study complied with Good Clinical Practices. The study sponsor
created a computer-generated, gender-stratiﬁed randomization sche-
dule provided in sealed consecutively-numbered envelopes for each
study site. Study formula was assigned by opening the next sequential
envelope from the appropriate set at the study site. Study formulas
were each designated by two unique codes known only to the sponsor
and dispensed to parents at each study visit prior to completion or
withdrawal. Neither the product labels nor the sealed envelopes
allowed direct unblinding by the study site. Personnel responsible for
monitoring the study were also blinded to study product identiﬁcation.
Blinding for a participant could be broken by study sponsor personnel
in the event of a medical emergency in which knowledge of the study
formula was critical to the participant's management. In this study, it
was not necessary to break the study code prematurely.
Participants were randomly assigned to receive a routine cow's
milk-based infant formula (Control; marketed Enfamil®, Mead
Johnson Nutrition, Evansville, IN) with the current DHA source
(DHASCO; 17 mg/100 kcal) or an investigational cow's milk-based
formula with an alternative DHA source (DHASCO-B; 17 mg/100 kcal)
from 14 to 120 days of age (Table 1). DHASCO-B is a new single cell oil
with DHA as the predominant fatty acid constituent (~40% of total
fatty acids). The GRAS notice for DHASCO-B from the manufacturer
(DSM Nutritional Products, Columbia, MD) provides detailed speciﬁ-
cations; brieﬂy, other major fatty acids ( > 1% of total fatty acids)
include myristic acid (~1%); palmitic acid (~13–14%); stearic acid
(~1.5%); oleic acid (~25%); docosapentaenoic acid (DPAn-6; ~3%);
and eicosapentaenoic acid (EPA; ~6%, maximum 10%) as well as
comprehensive information regarding the characterization of the
marine algae Schizochytrium sp., method of DHASCO-B manufacture
and extraction, and toxicology reporting to support safety of use [23].
Study formulas were provided as ready-to-use (RTU) liquids (20 cal/
ﬂuid ounce) with ARASCO as the source of ARA (34 mg/100 kcal) and
a prebiotic blend of PDX (Litesse® Two Polydextrose; Danisco) and
GOS (Vivinal® GOS Galactooligosaccharide; Friesland Foods Domo) at
4 g/L (1:1 ratio).
For formulas in the current study, fatty acid composition was
representative of previously studied formulas with DHASCO formu-
Table 1
Nutrient composition per 100 kcal.
Nutrient Study Formula, target values
Control DHASCO-B
Total Protein, g* 2.1 2.1
Total Fat, g† 5.3 5.3
Total Carbohydrate, g‡ 11.2 11.2
Vitamin A, IU 300 300
Vitamin D, IU 60 60
Vitamin E, IU 2 2
Vitamin K, mcg 9 9
Thiamin, mcg 80 80
Riboﬂavin, mcg 140 140
Vitamin B6, mcg 60 60
Vitamin B12, mcg 0.3 0.3
Niacin, mcg 1000 1000
Folic Acid, mcg 16 16
Pantothenic Acid, mcg 500 500
Biotin, mcg 3 3
Vitamin C, mg 12 12
Choline, mg 24 24
Inositol, mg 6 6
Calcium, mg 78 78
Phosphorus, mg 43 43
Magnesium, mg 8 8
Iron, mg 1.8 1.8
Zinc, mg 1 1
Manganese, mcg 15 15
Copper, mcg 75 75
Iodine, mcg 15 15
Selenium, mcg 2.8 2.8
Sodium, mg 27 27
Potassium, mg 108 108
Chloride, mg 63 63
* Sources of protein: skim milk and whey protein concentrate.
† Sources of fat: base blend of palm olein, soybean, coconut, and high oleic sunﬂower
oils; ARA from fungal oil (ARASCO) as a source of ARA (34 mg/100 kcal) and DHA from
algal oils (Control: DHASCO; Investigational: DHASCO-B) as a source of DHA (17 mg/
100 kcal).
‡ Sources of carbohydrate: 10.6 g lactose and 0.6 g prebiotic blend of PDX and GOS
(1:1 ratio, 4 g/L).
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lated to contain 17 mg DHA/100 kcal [2,7,11,13]. Study formula fatty
acid composition as a percent of total fatty acids (wt/wt) is presented as
supplemental information (Supplemental Table 1). Nutrients in infant
formulas, including DHA, are formulated to meet expert recommenda-
tions and regulatory requirements, as well as mitigate analytical and
manufacturing variability, and provide integrity over shelf life. Quality
control and Good Manufacturing Practices ensure target nutrient
values remain within a narrow range.
2.3. Study objectives and outcomes
2.3.1. Growth and tolerance
The objective was to evaluate growth and tolerance in healthy, term
infants. Anthropometric measures (body weight, length, and head
circumference) were recorded at study visits corresponding to 14, 30,
42, 60, 90, and 120 days of age. Parents completed a 24-hour recall of
tolerance (fussiness and gassiness) and stool characteristics (frequency
and consistency) at all study visits and study formula intake (ﬂuid oz/
day) beginning at the 30 days of age visit. Responses were scaled for
amount of gas (none, slight amount, moderate amount, excessive
amount); fussiness (not fussy, slightly fussy, moderately fussy, very
fussy, extremely fussy); and stool consistency (hard, formed, soft,
unformed or seedy, watery). Adverse events were coded according to
speciﬁc event (e.g. otitis media, colic, etc.) and the body system
involved including: Body as a Whole; Cardiovascular; Endocrine;
Eye, Ears, Nose, and Throat; Gastrointestinal; Metabolic and
Nutrition; Musculoskeletal; Nervous; Respiratory; Skin; and
Urogenital.
2.3.2. Fatty acid analysis
At ﬁve investigative sites experienced in handling clinical blood
samples and with appropriate storage facilities, blood samples at 120
days of age were collected by venipuncture into EDTA Vacutainer
tubes. For fatty acid analysis, plasma and RBC were separated by
centrifugation and frozen. Samples were shipped on dry ice to the
Retina Foundation of the Southwest (Dallas, TX) where lipids were
extracted, fractionated by thin-layer chromatography (plasma phos-
pholipids [PPLs] only), and analyzed by capillary column gas chroma-
tography as previously described [2]. Fatty acid methyl esters from
RBC lipids and the PPL fraction were reported as concentrations (μg/
mL) and as a percent of total fatty acids (wt/wt).
2.4. Statistical methods
The primary outcome was weight growth rate from 14 to 120 days
of age. The sample size was chosen to detect a clinically relevant
diﬀerence of 3 g/day in weight gain from 14 to 120 days of age (80%
power). Assuming a standard deviation of 6.5 g/day for male and 5.5 g/
day for female participants, approximately 91 males and 66 females
were needed to enroll in each group with the expectation that 59 male
and 43 female participants per study group would complete the study.
Analysis of variance (ANOVA) was used to assess growth rates from 14
to 30, 42, 60, 90, or 120 days of age calculated for each participant by
linear regression of weight on age. Mean weight growth rates by gender
for the investigational formula group was compared with the control
using a one-tailed test as outlined in guidance provided by the
American Academy of Pediatrics (AAP) Task Force on Clinical
Testing of Infant Formulas [32].
Secondary outcomes included blood lipids, other anthropometric
and tolerance measures, and medically-conﬁrmed adverse events. Per
the United States FDA guidance for bioequivalence studies [33], a pre-
speciﬁed equivalence range (0.80-1.25) for total RBC DHA concentra-
tion at 120 days of age was used to establish the bioequivalence of the
two study formulas with respect to DHA. Assuming a coeﬃcient of
variation of 0.2 (95% power), a subset of approximately 22 participants
per formula group were required to complete the study and have a
blood sample drawn at 120 days of age. The natural logs of the total
RBC DHA concentration data were analyzed by ANOVA with a term for
study group included. A 90% conﬁdence interval (CI) for the diﬀerence
in the total RBC DHA means (DHASCO-B minus Control) was
calculated. The antilogs of the conﬁdence limits obtained formed a
90% CI for the ratio of the geometric means between the investigational
(DHASCO-B) and Control formulas. If the resulting CI fell within the
pre-speciﬁed equivalence range (0.80-1.25), then equivalence with
respect to DHA was established.
Achieved weight, length, and head circumference; length and head
circumference growth rates; formula intake; stool frequency; and total
RBC and plasma phospholipid (PPL) fatty acid data were analyzed by
ANOVA. Stool consistency, fussiness, and gas were analyzed using the
Cochran-Mantel-Haenszel (CMH) row means score test. Incidence of
adverse events was analyzed using Fisher's exact test. With the
exception of p-values reported from the analysis of weight gain based
on one-tailed tests, all other p-values reported were based on two-tailed
tests. All testing was conducted at α=0.05. All analyses were conducted
using SAS version 9.2 (Cary, NC).
3. Results
3.1. Participants
A total of 360 participants were enrolled and randomized (Control:
n=184; DHASCO-B: n=176). Participants who were randomized but
consumed no study formula (Control: n=2; DHASCO-B: n=4) were not
included in subsequent analyses (Fig. 1). No diﬀerences in body weight,
length, or head circumference were observed by gender between groups
at study enrollment (Table 2). Birth anthropometric measures as well
as gender, race, and ethnic distribution were also similar between
groups (data not shown). No statistically signiﬁcant group diﬀerences
were detected for study discontinuation (Control: n=42, 23%;
DHASCO-B: n=45, 26%) or discontinuation related to study formula
(Control: n=19, 10%; DHASCO-B: n=11, 6%). In the total study
population, 27 participants (8%) discontinued due to formula intoler-
ance as determined by the study investigator with gas (Control: n=11;
DHASCO-B: n=3) and fussiness (Control: n=9; DHASCO-B: n=5) as
the most common indicators. Parental decision was the most common
reason for discontinuation unrelated to study formula (42 participants,
12%). A total of 267 infants completed the study (Control: n=140;
DHASCO-B: n=127).
3.2. Growth
Growth rates were analyzed from 14 to 120 days of age. No
statistically signiﬁcant group diﬀerences by gender in the primary
outcome, weight growth rate from day 14-120, were detected (Table 3).
No statistically signiﬁcant group diﬀerences by gender in weight,
length, or head circumference growth rates were detected for any age
range. In addition, no signiﬁcant group diﬀerences were observed for
mean achieved weight, length, or head circumference at any measured
time point. Finally, mean achieved weight plotted on the WHO weight-
for-age standard growth chart [34,35] tracked along the 50th percentile
for males (Fig. 2) and remained between the 25th and 50th percentiles
for females (Fig. 3) at all measured time points.
3.3. Tolerance
No group diﬀerences in parent-reported gassiness and fussiness or
stool characteristics were detected at any time point assessed (data not
shown). The amount of gas most commonly reported was “slight” or
“moderate” and fussiness was most often characterized as “slightly
fussy” in both groups. For stool consistency the majority of participants
in both groups from enrollment to day 120 were reported to have a
“soft” or “unformed or seedy” stool consistency. No group diﬀerences in
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parent-reported study formula intake by gender were detected any time
point assessed (data not shown). In addition, mean reported intakes
increased from day 30 to 120 for both groups by gender, indicating
normal intake for this time period. No group diﬀerence was detected in
the number of participants for whom at least one medically-conﬁrmed
adverse event was reported (Control: n=135, 74%; DHASCO-B: n=121,
70%; P=0.476). The incidence of adverse events categorized within
Body as a Whole; Cardiovascular; Endocrine; Eyes, Ears, Nose, and
Throat; Metabolic and Nutrition; Musculoskeletal; Nervous System;
Skin; or Urogenital systems were generally low with no statistically
signiﬁcant group diﬀerences for speciﬁc events. In the Gastrointestinal
(GI) and Respiratory Systems no signiﬁcant group diﬀerences for
speciﬁc adverse events were detected; gastroesophageal reﬂux
(Control: n=24, 13%; DHASCO-B: n=35, 20%) and upper respiratory
infection (Control: n=37, 20%; DHASCO-B: n=28, 16%) were the most
commonly reported speciﬁc adverse events by category. Any medically-
conﬁrmed adverse event was considered serious if it met one or more of
the following criteria: resulted in death, was life-threatening, required
inpatient hospitalization or prolongation of existing hospitalization,
resulted in persistent or signiﬁcant disability/incapacity, or was a
congenital anomaly/birth defect. A total of 9 participants experienced
serious adverse events (Control: n=5, 3%; DHASCO-B: n=4, 2%). All
serious adverse events were individually evaluated by study site
physicians and each was determined unrelated to study formulas.
3.4. Blood lipids
Total RBC and PPL fatty acids (mean ± SE) as concentrations (μg/
mL) (Table 4) and percent of total fatty acids (wt/wt) (Table 5) from
blood lipid fractions at 120 days of age were evaluated. No group
diﬀerences in RBC total or individual saturated and monounsaturated
fatty acid concentrations or as a percent of total fatty acids were
detected. With the exception of signiﬁcantly lower PPL lignoceric acid
(24:0), oleic acid (18:1), and total monounsaturated fatty acids as a
percent of total fatty acids in the Control compared to the DHASCO-B
group, no other group diﬀerences in PPL saturated and monounsatu-
rated fatty acids were detected (concentration and percent of total fatty
acids). No statistically signiﬁcant group diﬀerences were detected in
RBC or PPL total n-3 or n-6 PUFAs (concentration and percent of total
fatty acids). With the exception of signiﬁcantly lower RBC and PPL EPA
(20:5n-3), DPAn-3 (22:5n-3), and DPAn-6 (22:5n-6) for the Control
compared to DHASCO-B group, no other group diﬀerences in indivi-
dual RBC or PPL n-3 or n-6 PUFAs were detected (concentration and
percent of total fatty acids). In particular, no group diﬀerences in RBC
or PPL DHA (22:6n-3) or ARA (20:4n-6) were detected.
3.5. DHA equivalence
The calculated 90% CI for the ratio of the mean (geometric) DHA
concentration (µg/mL) in total RBCs for participants receiving the
investigational compared to the Control formula needed to fall within
an equivalence limit of 80–125% in order to conclude the equivalence
Participants randomized
    males, n = 202
females, n = 158
Control
    males, n = 102
females, n = 82
DHASCO-B
    males, n = 100
females, n = 76
Control
    males, n = 102
females, n = 80
DHASCO-B
    males, n = 97
females, n = 75
Completed
    males, n = 81
females, n = 59
Completed
    males, n = 70
females, n = 57
Did not consume study formula
    males, n = 0
females, n = 2
Did not consume study formula
    males, n = 3
females, n = 1
Discontinued
Formula-related
males, n = 5 
females, n = 6 
Not formula-related
males, n = 22
females, n = 12 
Discontinued
Formula-related
males, n = 11 
females, n = 9 
Not formula-related
males, n = 10
females, n = 12 
Fig. 1. Flow of study participants.
Table 2
Infant characteristics at study entry.
Study Group
Control DHASCO-B
Total number of participants 182 172
Number of males/females 102/80 97/75
males*
Weight (g) 3675.1 ± 45.4 3675.7 ± 46.6
Length (cm) 52.2 ± 0.2 52.2 ± 0.2
Head circumference (cm) 36.2 ± 0.1 36.3 ± 0.1
females*
Weight (g) 3406.3 ± 42.2 3400.7 ± 43.6
Length (cm) 51.1 ± 0.2 50.9 ± 0.2
Head circumference (cm) 35.4 ± 0.1 35.5 ± 0.1
* Mean ± standard error (SE)
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with respect to DHA. For total RBC DHA, conﬁdence interval for the
investigational relative to the Control group was 91–104%.
4. Discussion
This study demonstrated that an investigational routine intact
protein cow's milk-based ready-to-use (RTU) liquid formula with
DHASCO-B (source of DHA, 17 mg/100 kcal), ARASCO (source of
ARA, 34 mg/100 kcal) and a prebiotic blend (PDX and GOS; 1:1 ratio,
4 g/L) was safe and well-tolerated when fed to healthy term infants
from 14 to 120 days of age. The investigational formula was also
associated with normal growth throughout the study. As outlined in
guidance provided by the AAP Task Force on Clinical Testing of Infant
Formulas, rate of weight gain (g/day) is used as the most important
parameter in clinical evaluation of nutritional suitability of infant
formulas [32]. No statistically signiﬁcant group diﬀerences were
observed for weight, length, or head circumference growth rates from
14 to 120 days of age. Mean achieved weight for males and females
were within the 25th and 75th percentiles of the WHO weight-for-age
growth chart from 14 to 120 days of age and no group diﬀerences for
mean achieved weight, length, or head circumference by gender were
detected at any measured time point. Calculated conﬁdence intervals of
DHA concentrations in total RBC fell within the pre-speciﬁed equiva-
lence limit of 80–125%, thus establishing equivalence of study
formulas with respect to DHA.
Postnatal diet, in combination with LCPUFA status at birth—in
itself a function of maternal fatty acid status and reﬂective of maternal
diet and genetic polymorphisms—inﬂuences postnatal changes in
infant blood LCPUFA status across populations [36,37]. DHA incor-
poration into RBCs is a practical surrogate for measuring DHA
accumulation into the brain [2,38] because DHA in RBC and neural
membranes exhibit a relative response to dietary modiﬁcation [39].
Previous studies with formula with DHASCO as the source of DHA
have demonstrated signiﬁcant positive correlations between RBC DHA
Table 3
Weight, length, and head circumference growth rates from 14 days to 30, 42, 60, 90, and 120 days of age.
Growth rate*
Gender Day Group (n) Weight
(g/day)
Length
(cm/day)
Head
circumference
(cm/day)
male 30 Control (94) 41.6 ± 1.2 0.13 ± 0.007 0.10 ± 0.004
DHASCO-B (90) 39.6 ± 1.2 0.13 ± 0.008 0.09 ± 0.004
42 Control (87) 41.0 ± 1.0 0.13 ± 0.004 0.09 ± 0.003
DHASCO-B (86) 39.0 ± 1.0 0.13 ± 0.004 0.08 ± 0.003
60 Control (86) 37.9 ± 0.9 0.12 ± 0.003 0.07 ± 0.002
DHASCO-B (80) 37.7 ± 0.9 0.12 ± 0.003 0.07 ± 0.002
90 Control (84) 33.8 ± 0.8 0.11 ± 0.002 0.06 ± 0.001
DHASCO-B (73) 33.2 ± 0.9 0.12 ± 0.002 0.06 ± 0.001
120 Control (81) 30.5 ± 0.7 0.11 ± 0.002 0.06 ± 0.001
DHASCO-B (71) 30.3 ± 0.8 0.11 ± 0.002 0.05 ± 0.001
female 30 Control (66) 34.0 ± 1.2 0.13 ± 0.008 0.08 ± 0.004
DHASCO-B (72) 35.1 ± 1.2 0.13 ± 0.007 0.08 ± 0.004
42 Control (64) 32.1 ± 1.0 0.13 ± 0.005 0.08 ± 0.002
DHASCO-B (66) 33.8 ± 1.0 0.12 ± 0.005 0.07 ± 0.002
60 Control (61) 29.7 ± 0.8 0.12 ± 0.004 0.07 ± 0.002
DHASCO-B (64) 31.3 ± 0.8 0.11 ± 0.004 0.07 ± 0.002
90 Control (59) 27.6 ± 0.7 0.10 ± 0.002 0.06 ± 0.001
DHASCO-B (60) 28.2 ± 0.7 0.10 ± 0.002 0.06 ± 0.001
120 Control (59) 25.9 ± 0.6 0.10 ± 0.002 0.05 ± 0.001
DHASCO-B (57) 26.7 ± 0.6 0.10 ± 0.002 0.05 ± 0.001
* Mean ± standard error (SE)
Fig. 2. Mean achieved weight for male participants with World Health Organization
(WHO) reference percentiles (2nd to 98th) from 14 to 120 days of age. Control, stars;
DHASCO-B, circles.
Fig. 3. Mean achieved weight for female participants with World Health Organization
(WHO) reference percentiles (2nd to 98th) from 14 to 120 days of age. Control, stars;
DHASCO-B, circles.
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and improved cognitive and visual outcomes [2,7,8,11–16]. Results of
the current study in healthy infants from 14 to 120 days of age
demonstrated routine infant formulas with DHASCO or DHASCO-B as
the source of DHA were associated with equivalent concentrations of
circulating total RBC DHA. In addition, group RBC DHA mean
concentrations in the current study at 120 days of age (Control:
90.2 µg/mL; DHASCO-B: 88.1 µg/mL) were within the previously
reported range (77–113 µg/mL) for infants receiving infant formula
with DHASCO as the source of DHA (formulated at 17 mg/100 kcal) up
to 120 days of age [2,7,11,13]. Similarly, group RBC ARA mean
concentrations in the current study at 120 days of age (Control:
243.6 µg/mL; DHASCO-B: 240.8 µg/mL) were within the previously
reported range (178–268 µg/mL) for infants receiving formula with
ARASCO as the source ARA (formulated at 34 mg/100 kcal) up to 120
days of age [2,7,11,40]. Consequently, infant formula with DHASCO-B
(as a source of DHA) produces RBC DHA within the range representa-
tive of the totality of previous clinical data and comparable to previous
clinical studies with infants receiving formula with DHASCO (as an
equivalent source of DHA). The current data therefore suggests the
availability of circulating DHA for central nervous system development
and function in infants.
Recently-consumed fatty acids generally comprise a greater propor-
tion of PPL compared to RBC composition in the postprandial period
[41]. In the current study blood was collected in the unfasted state,
thus RBC would be inﬂuenced to a lesser extent by recent dietary intake
than PPL and therefore considered a more deﬁnitive marker of fatty
acid content for other body tissues. Consequently, the few diﬀerences
detected in PPL saturated and monounsaturated fatty acids were not
considered clinically relevant. No statistically signiﬁcant group diﬀer-
ences were detected in RBC or PPL total n-3 or n-6 PUFAs. With the
exception of lower RBC and PPL EPA (20:5n-3), DPAn-3 (22:5n-3),
and DPAn-6 (22:5n-6) for the Control compared to DHASCO-B group,
no other group diﬀerences in RBC or PPL individual n-3 or n-6 PUFAs
were detected. Unlike DHASCO, as previously noted, DHASCO-B is
also a source of some EPA (~6%) and DPAn-6 (~3% of total fatty acids)
[23], which are fatty acids also present in human milk [24]. These
distinctions in single cell oil fatty acid composition would be less
pronounced in the ﬁnal study formula composition (each < 0.1% of
total fatty acids, as estimated) but potentially still reﬂective of very
minor group diﬀerences observed in circulating EPA and DPAn-6. In
both DHASCO and DHASCO-B, DPAn-3 is present in extremely low
quantities ( < 1% of total fatty acids) [23]. However, endogenous
synthesis of DPAn-3 from EPA may occur and could potentially
contribute to blood fatty acid concentrations [42,43]. Global infant
formula standards (such as CODEX Alimentarius and those in the
European Union, China, and Australia) that regulate DHA as an
Table 4
Total RBC and PPL fatty acid concentrations (μg/mL) at 120 days of age*.
RBC Plasma phospholipids (PPLs)
Fatty Acid Control DHASCO-B Control DHASCO-B
Saturated 652.2 (12.21) 635.4 (13.71) 374.8 (10.56) 358.7 (11.85)
14:0 Myristic 7.5 (0.66) 6.9 (0.74) 1.2 (0.06) 1.2 (0.07)
15:0 n-Pentadecanoic 0.7 (0.03) 0.7 (0.03) 0.4 (0.02) 0.4 (0.02)
16:0 Palmitic 380.9 (7.65) 369.9 (8.58) 215.8 (6.18) 205.3 (6.94)
17:0 Margaric 2.6 (0.06) 2.5 (0.06) 1.7 (0.06) 1.6 (0.06)
18:0 Stearic 210.3 (4.53) 205.6 (5.09) 136.4 (4.16) 131.0 (4.67)
20:0 Arachidic 7.1 (0.16) 6.8 (0.18) 3.5 (0.11) 3.3 (0.12)
22:0 Behenic 14.0 (0.25) 13.9 (0.28) 8.4 (0.26) 8.3 (0.30)
24:0 Lignoceric 29.1 (0.66) 29.0 (0.75) 7.4 (0.22) 7.5 (0.25)
Monounsaturated 330.5 (11.23) 320.6 (12.61) 86.2 (2.89) 86.7 (3.25)
14:1 Myristoleic 0.8 (0.28) 1.2 (0.31) 0.2 (0.2) 0.1 (0.03)
16:1 Palmitoleic 3.4 (0.32) 3.3 (0.36) 1.1 (0.08) 1.1 (0.09)
18:1 Oleic 287.7 (11.12) 276.6 (12.48) 75.1 (2.72) 75.3 (3.05)
20:1 Gadoleic 4.3 (0.12) 4.3 (0.13) 1.3 (0.05) 1.2 (0.05)
22:1 Erucic 1.7 (0.09) 1.9 (0.10) 0.8 (0.04) 0.7 (0.05)
24:1 Nervonic 32.6 (0.74) 33.4 (0.83) 7.9 (0.23) 8.2 (0.26)
n−3 PUFA 105.5 (2.64) 107.0 (2.97) 52.1 (1.66) 50.1 (1.86)
18:3n−3 α-linolenic 4.4 (0.30) 3.8 (0.34) 1.0 (0.04) 0.9 (0.05)
18:4n−3 Octatetraenoic 0.9 (0.08) 0.9 (0.09) 0.0 (0.00) 0.0 (0.00)
20:3n−3 Eicosatrienoic 0.3 (0.02) 0.3 (0.02) 0.1 (0.01) 0.1 (0.01)
20:5n−3 Eicosapentaenoic (EPA) 1.7 (0.10) 3.4 (0.11)† 0.9 (0.07) 1.9 (0.07)†
22:3n−3 Docosatrienoic ND ND ND ND
22:5n−3 Docosapentaenoic (DPAn−3) 7.9 (0.34) 10.5 (0.38)† 2.1 (0.10) 2.8 (0.11)†
22:6n−3 Docosahexaenoic (DHA) 90.2 (2.31) 88.1 (2.59) 48.0 (1.56) 44.3 (1.75)
n−6 PUFA 559.3 (12.33) 530.9 (13.84) 311.1 (9.14) 297.8 (10.25)
18:2n−6 Linoleic 245.1 (9.51) 218.8 (10.67) 176.3 (5.61) 167.2 (6.29)
18:3n−6 γ-linolenic 0.6 (0.07) 0.5 (0.07) 0.3 (0.04) 0.3 (0.04)
20:2n−6 Eicosadienoic 4.6 (0.14) 4.3 (0.15) 2.1 (0.07) 1.9 (0.08)
20:3n−6 Dihomo-γ-linolenic 14.0 (0.44) 14.7 (0.50) 10.5 (0.44) 10.7 (0.50)
20:4n−6 Arachidonic (ARA) 243.6 (4.68) 240.8 (5.25) 117.3 (3.50) 112.5 (3.93)
22:2n−6 Docosadienoic 0.7 (0.04) 0.6 (0.04) 0.1 (0.01) 0.1 (0.01)
22:4n−6 Docosatetraenoic 44.5 (1.28) 43.4 (1.43) 3.1 (0.09) 3.0 (0.10)
22:5n−6 Docosapentaenoic (DPAn−6) 6.2 (0.29) 7.8 (0.32)† 1.5 (0.10) 2.0 (0.11)†
n−9 PUFA
20:3n−9 Eicosatrienoic 0.02 (0.02) 0.02 (0.03) 0.1 (0.01) 0.1 (0.01)
Total 1647.7 (34.97) 1594.1 (39.25) 824.4 (23.73) 793.4 (26.63)
* Mean ± standard error (SE); Participants: Control, 34; DHASCO-B, 27; not detected = ND.
† Statistically signiﬁcant group diﬀerence, P < 0.001.
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optional ingredient [44–47] or compositional requirement [28] recog-
nize EPA can be present in sources of LCPUFA and that the content of
EPA in formula for infants should not exceed the content of DHA. In
line with meeting these regulations, EPA is lower than DHA in
DHASCO-B (~6% compared to ~44% of total fatty acids). In the
current study, EPA, DPAn-3, and DPAn-6 were relatively minor
constituents of blood samples (each < 1% of total fatty acids).
Consequently, the diﬀerences detected in these blood fatty acids did
not aﬀect formula safety and tolerance outcomes or association with
normal infant growth and therefore not considered clinically relevant.
Despite small diﬀerences in blood fatty acid composition, both
DHASCO and DHASCO-B represent equally bioavailable sources of
DHA.
Overall, acceptance and tolerance of study formulas were good. No
diﬀerences in study discontinuation due to study formula were
detected. No signiﬁcant group diﬀerences were detected in fussiness
or gassiness and stool frequency or consistency. Stool consistency was
in the soft or seedy range for both groups at all measured time points.
The current results are consistent with our previous reports in which
use of routine formulas that have PDX and GOS (4 g/L; 1:1 ratio) was
well tolerated, safe, promoted normal growth and produced softer
stools in healthy, term infants [48,49] and produced a biﬁdogenic eﬀect
closer to human milk [50] compared to infants receiving formulas with
no PDX and GOS.
5. Conclusion
In the current study in healthy, term infants receiving a routine
intact protein cow's milk-based formula with DHASCO-B as the source
of DHA (17 mg/100 kcal), ARASCO as the source of ARA (34 mg/
100 kcal), and a prebiotic blend (PDX and GOS; 1:1 ratio, 4 g/L) was
well-tolerated and supported normal growth. In addition, calculated
conﬁdence intervals of DHA concentrations in total RBC fell within the
pre-speciﬁed equivalence limit of 80–125%, suggesting that routine
infant formula with the existing or alternative source of DHA were
associated with equivalent concentrations of circulating total RBC
DHA.
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Table 5
Total RBC and PPL fatty acids as a percent of total fatty acids (wt/wt) at 120 days of age*.
RBC Plasma phospholipids (PPLs)
Fatty Acid Control DHASCO-B Control DHASCO-B
Saturated 39.73 (0.26) 39.88 (0.29) 45.50 (0.13) 45.22 (0.15)
14:0 Myristic 0.44 (0.03) 0.42 (0.03) 0.15 (0.01) 0.15 (0.01)
15:0 n-Pentadecanoic 0.04 (0.00) 0.04 (0.00) 0.05 (0.00) 0.06 (0.00)
16:0 Palmitic 23.17 (0.17) 23.22 (0.19) 26.21 (0.20) 25.91 (0.22)
17:0 Margaric 0.16 (0.00) 0.16 (0.00) 0.21 (0.00) 0.21 (0.00)
18:0 Stearic 12.83 (0.16) 12.89 (0.18) 16.55 (0.17) 16.46 (0.20)
20:0 Arachidic 0.43 (0.01) 0.43 (0.01) 0.42 (0.01) 0.42 (0.01)
22:0 Behenic 0.86 (0.02) 0.88 (0.02) 1.02 (0.02) 1.06 (0.02)
24:0 Lignoceric 1.79 (0.05) 1.83 (0.06) 0.90 (0.02) 0.96 (0.02)†
Monounsaturated 19.89 (0.30) 20.06 (0.34) 10.45 (0.13) 10.91 (0.14)†
14:1 Myristoleic 0.05 (0.02) 0.07 (0.02) 0.02 (0.00) 0.01 (0.00)
16:1 Palmitoleic 0.20 (0.02) 0.20 (0.02) 0.13 (0.01) 0.14 (0.01)
18:1 Oleic 17.25 (0.33) 17.28 (0.37) 9.08 (0.12) 9.44 (0.13)†
20:1 Gadoleic 0.26 (0.01) 0.27 (0.01) 0.15 (0.00) 0.15 (0.00)
22:1 Erucic 0.10 (0.00) 0.12 (0.01) 0.10 (0.01) 0.10 (0.01)
24:1 Nervonic 2.02 (0.06) 2.11 (0.07) 0.97 (0.04) 1.07 (0.04)
n−3 PUFA 6.45 (0.13) 6.71 (0.14) 6.34 (0.10) 6.32 (0.12)
18:3n−3 α-linolenic 0.26 (0.01) 0.23 (0.02) 0.12 (0.00) 0.11 (0.01)
18:4n−3 Octatetraenoic 0.06 (0.01) 0.06 (0.01) 0.00 (0.00) 0.00 (0.00)
20:3n−3 Eicosatrienoic 0.02 (0.00) 0.02 (0.00) 0.02 (0.00) 0.02 (0.00)
20:5n−3 Eicosapentaenoic (EPA) 0.11 (0.01) 0.22 (0.01)† 0.11 (0.01) 0.25 (0.01)†
22:3n−3 Docosatrienoic ND ND ND ND
22:5n−3 Docosapentaenoic (DPAn−3) 0.49 (0.02) 0.66 (0.02)† 0.25 (0.01) 0.35 (0.01)†
22:6n−3 Docosahexaenoic (DHA) 5.52 (0.12) 5.52 (0.13) 5.83 (0.10) 5.59 (0.12)
n−6 PUFA 33.92 (0.28) 33.35 (0.32) 37.70 (0.15) 37.54 (0.17)
18:2n−6 Linoleic 14.68 (0.34) 13.72 (0.39) 21.30 (0.26) 21.10 (0.29)
18:3n−6 γ-linolenic 0.03 (0.00) 0.03 (0.00) 0.04 (0.00) 0.04 (0.00)
20:2n−6 Eicosadienoic 0.28 (0.01) 0.27 (0.01) 0.26 (0.01) 0.24 (0.01)
20:3n−6 Dihomo-γ-linolenic 0.85 (0.03) 0.93 (0.03) 1.27 (0.04) 1.36 (0.04)
20:4n−6 Arachidonic (ARA) 14.90 (0.24) 15.15 (0.27) 14.27 (0.17) 14.16 (0.19)
22:2n−6 Docosadienoic 0.04 (0.00) 0.04 (0.00) 0.01 (0.00) 0.01 (0.00)
22:4n−6 Docosatetraenoic 2.75 (0.09) 2.73 (0.10) 0.37 (0.01) 0.38 (0.01)
22:5n−6 Docosapentaenoic (DPAn−6) 0.38 (0.02) 0.49 (0.02)† 0.18 (0.01) 0.25 (0.01)†
n−9 PUFA
20:3n−9 Eicosatrienoic 0.01 (0.00) 0.01 (0.00) 0.01 (0.00) 0.01 (0.00)
* Mean ± standard error (SE); Participants: Control, 34; DHASCO-B, 27; not detected = ND.
† Statistically signiﬁcant group diﬀerence, P < 0.05.
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